Peanut Oral Immunotherapy Trial for People Over 16 Years
St Vincent’s Hospital Sydney is recruiting to an Australia-first research trial to help people over 16 years of age, who are living with peanut allergy. We are investigating the effectiveness of combining omalizumab with peanut oral immunotherapy in improving safety and tolerability of peanut immunotherapy in adults. This will not cure peanut allergy, but aims to improve safety and quality of life for those living with peanut allergy into adulthood.
We are seeking participants who are:
- over the age of 16 and have peanut allergy
- have not been admitted to ICU for a peanut reaction in the last 5 years
- not lactating, pregnant or planning pregnancy
- and able to commit to 18 study visits over 12 months (7 of the visits take between 4 to 6 hours)
Participants will be reimbursed for travel (e.g. taxi fares) and parking costs associated with study visits. Please note that all visits will be occurring at St Vincent’s Public Hospital Sydney.
This study has been approved by South West Sydney Local Health District Human Research Ethics Committee. Reference number 2019/ETH13494 and recruitment will end in November 2021.
We would like to acknowledge The Balnaves Foundation, St Vincent’s Curran Foundation and SPHERE Triple I for their support of this study.
Allergy and Immunology Foundation of Australasia (AIFA)
AIFA was established in 2013 by ASCIA to fund medical research into allergy and other immune diseases. Donate to AIFA at www.allergyimmunology.org.au/donate
To apply for an AIFA research grant the Chief Investigator must be an ASCIA member. Download an Expression of Interest form at www.allergyimmunology.org.au/grants
For information about research projects funded by AIFA grants go to www.allergyimmunology.org.au/projects
Content updated March 2021